Exploring Structural Determinants of Bias among D4 Subtype-Selective Dopamine Receptor Agonists

被引:3
|
作者
Grassl, Fabian
Bock, Leonard [1 ]
Gonzalez, Alvaro Huete-Huerta [1 ]
Schiller, Martin [1 ]
Gmeiner, Peter [1 ]
Koenig, Joerg [2 ]
Fromm, Martin F. [2 ]
Huebner, Harald [1 ]
Heinrich, Markus R. [1 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg, Dept Chem & Pharm, Pharmaceut Chem, D-91058 Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nurnberg, Inst Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany
关键词
D-4; RECEPTOR; ANOREXIA-NERVOSA; 7-REPEAT ALLELE; PENILE ERECTION; P-GLYCOPROTEIN; D2; DISCOVERY; GENE; HYPERACTIVITY; POLYMORPHISMS;
D O I
10.1021/acs.jmedchem.3c00537
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The high affinity dopamine D-4 receptor ligandAPH199and derivatives thereof exhibit bias toward the G(i) signalingpathway over & beta;-arrestin recruitment compared to quinpirole.Based on APH199, two novel groups of D-4 subtype selectiveligands were designed and evaluated, in which the original benzylphenylsemicarbazide substructure was replaced by either a biphenylmethylurea or a biphenyl urea moiety. Functional assays revealed a rangeof different bias profiles among the newly synthesized compounds,namely, with regard to efficacy, potency, and GRK2 dependency, inwhich bias factors range from 1 to over 300 and activation from 15%to over 98% compared to quinpirole. These observations demonstratethat within bias, an even more precise tuning toward a particularprofile is possible, which in a general sense couldbecome an important aspect in future drug development. Docking studiesenabled further insight into the role of the ECL2 and the EPB in theemergence of bias, thereby taking advantage of the diversity of functionallyselective D-4 agonists now available.
引用
收藏
页码:9710 / 9730
页数:21
相关论文
共 50 条
  • [1] DOPAMINE-RECEPTOR SUBTYPE-SELECTIVE AGONISTS IN THE TREATMENT OF PARKINSONS-DISEASE
    CHASE, TN
    METMAN, LV
    BRAVI, D
    ROBERTS, JW
    SIBLEY, DR
    MOURADIAN, MM
    CLINICAL NEUROPHARMACOLOGY, 1995, 18 : S207 - S215
  • [2] Exploring the potential for subtype-selective muscarinic agonists in glaucoma
    Gil, D
    Spalding, T
    Kharlamb, A
    Skjaerbaek, N
    Uldam, A
    Trotter, C
    Li, DH
    WoldeMussie, E
    Wheeler, L
    Brann, M
    LIFE SCIENCES, 2001, 68 (22-23) : 2601 - 2604
  • [3] Selective dopamine D4 receptor antagonists
    Sanner, MA
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (04) : 383 - 393
  • [4] D4 dopamine receptor high-resolution structures enable the discovery of selective agonists
    Wang, Sheng
    Wacker, Daniel
    Levit, Anat
    Che, Tao
    Betz, Robin M.
    McCorvy, John D.
    Venkatakrishnan, A. J.
    Huang, Xi-Ping
    Dror, Ron O.
    Shoichet, Brian K.
    Roth, Bryan L.
    SCIENCE, 2017, 358 (6361) : 381 - +
  • [5] Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets
    Osinski, MA
    Uchic, ME
    Seifert, T
    Shaughnessy, TK
    Miller, LN
    Nakane, M
    Cox, BF
    Brioni, JD
    Moreland, RB
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2005, 81 (01) : 211 - 219
  • [6] Structural features of subtype-selective EP receptor modulators
    Markovic, Tijana
    Jakopin, Ziga
    Dolenc, Marija Sollner
    Mlinaric-Rascan, Irena
    DRUG DISCOVERY TODAY, 2017, 22 (01) : 57 - 71
  • [7] Exploring the structural space of estrogen receptor ligands: Subtype-selective binding and activation.
    Katzenellenbogen, JA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U301 - U301
  • [8] A new approach to finding specific dopamine D4 receptor agonists
    Morishita, H
    Shibata, K
    Sakata, N
    Kita, S
    Katsuragi, T
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 516 (02) : 145 - 150
  • [9] Crystal structure of dopamine receptor D4 bound to the subtype selective ligand, L745870
    Zhou, Ye
    Cao, Can
    He, Lingli
    Wang, Xianping
    Zhang, Xuejun Cai
    ELIFE, 2019, 8
  • [10] Effect of dopamine D4 receptor agonists on sleep architecture in rats
    Nakazawa, Shunsuke
    Nakamichi, Keiko
    Imai, Hideaki
    Ichihara, Junji
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2015, 63 : 6 - 13